Top Markets
Coin of the day
Immunotech Laboratories, Inc. Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc.

IMMB
Rang in Aktien #40594
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins... Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Aktienkurs
$0.0002
Zuletzt synchronisiert: 2026-08-12
Marktkapitalisierung
$114.99K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
100.00%
Land
US
Handel Immunotech Laboratories, Inc. (IMMB)

Kategorie

Dividendenrendite-Verlauf für Immunotech Laboratories, Inc. (IMMB)
Dividendenrendite (TTM) von Immunotech Laboratories, Inc. (Aktienkürzel: IMMB) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Immunotech Laboratories, Inc. (IMMB) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber